JAZZ
Jazz Pharmaceuticals PLC
NASDAQ: JAZZ · HEALTHCARE · BIOTECHNOLOGY
$199.92
-1.99% today
Updated 2026-04-29
Market cap
$12.54B
P/E ratio
—
P/S ratio
2.94x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$98 – $207
Volume
1.0M
Jazz Pharmaceuticals PLC (JAZZ) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-25.4%
Last 4 quarters
Revenue YoY growth
+10.1%
Most recent quarter
EPS YoY growth
+0.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.9%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-8.8%
2025-08-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-25 | $6.64 | +2.1% | $173.83 | $188.97 | +8.7% |
| 2025-11-05 | $8.13 | +36.4% | $137.82 | $134.05 | -2.7% |
| 2025-08-05 | $-8.25 | -8.3% | $116.10 | $105.93 | -8.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $6.51 | $6.64 | +2.1% | $1.20B | +10.1% |
| 2025-09-30 | $5.96 | $8.13 | +36.4% | $1.13B | +6.7% |
| 2025-06-30 | $-7.62 | $-8.25 | -8.3% | $1.05B | +2.1% |
| 2025-03-31 | $4.81 | $-1.52 | -131.6% | $897.84M | -0.5% |
| 2024-12-31 | $5.81 | $6.60 | +13.6% | $1.09B | +7.5% |
| 2024-09-30 | $5.50 | $6.61 | +20.2% | $1.05B | +8.5% |
| 2024-06-30 | $4.77 | $5.30 | +11.1% | $1.02B | +6.9% |
| 2024-03-31 | $4.18 | $2.68 | -35.9% | $901.98M | +1.0% |
| 2023-12-31 | $5.18 | $5.02 | -3.1% | $1.01B | — |
| 2023-09-30 | $4.93 | $4.84 | -1.8% | $972.14M | — |
| 2023-06-30 | $4.43 | $4.51 | +1.8% | $957.32M | — |
| 2023-03-31 | $4.24 | $3.95 | -6.8% | $892.81M | — |
Frequently asked questions
Has Jazz Pharmaceuticals PLC beaten earnings estimates?
Jazz Pharmaceuticals PLC has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -25.4% over the last 4 quarters.
How does JAZZ stock react to earnings?
JAZZ stock has moved an average of -0.9% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Jazz Pharmaceuticals PLC's revenue growth rate?
Jazz Pharmaceuticals PLC reported year-over-year revenue growth of +10.1% in its most recent quarter, with EPS growing +0.6% year-over-year.